Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 1 |
2024 | 2 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.
Cancers (Basel). 2024 Jan 28;16(3):556. doi: 10.3390/cancers16030556.
Cancers (Basel). 2024.
PMID: 38339307
Free PMC article.
Previously, we reported the modest but durable anticancer activity of regorafenib/nivolumab in mismatch repair-proficient (pMMR) refractory colorectal cancer in our I/Ib study. Our finding suggests the necessity of biomarkers for better selection of patients. ...Upregulati …
Previously, we reported the modest but durable anticancer activity of regorafenib/nivolumab in mismatch repair-proficient (pMMR) refractory …
The prognostic value of CMTR2 in patients with renal clear cell carcinoma.
Yu QX, Wang CN.
Yu QX, et al.
Asian J Surg. 2024 Jan;47(1):546-548. doi: 10.1016/j.asjsur.2023.09.102. Epub 2023 Sep 27.
Asian J Surg. 2024.
PMID: 37775386
Free article.
No abstract available.
Item in Clipboard
Cite
Cite